Gluformin Combi (Metformin Hydrochloride, Sitagliptin)

Gluformin Combi is prescribed as part of a comprehensive diabetes care plan that includes diet and exercise. It is used when monotherapy does not achieve adequate glycemic control.

• Adjunct to diet and exercise for adults with type 2 diabetes mellitus.
• Combination therapy when metformin alone is insufficient.
• May be considered when a patient requires both insulin sensitisation and incretin‑based therapy.
• Used to improve fasting and post‑prandial blood glucose levels.
• Often selected for patients who prefer a single‑pill regimen.

Side effects of Gluformin Combi vary in frequency and severity. Patients should be aware of both common and less frequent serious reactions.

Common

• Gastrointestinal upset such as nausea, diarrhoea, or abdominal discomfort.
• Upper respiratory tract infection symptoms.
• Headache.
• Mild hypoglycaemia, especially when combined with other glucose‑lowering agents.
• Dizziness.

Serious

• Lactic acidosis (rare, associated with metformin).
• Severe hypersensitivity reactions, including skin rash or angioedema.
• Pancreatitis.
• Significant renal impairment.
• Hepatic failure.

Before starting Gluformin Combi, certain health considerations should be reviewed to minimise risk.

• Assess renal function; metformin is contraindicated in severe renal impairment.
• Evaluate hepatic status, as liver disease may increase the risk of lactic acidosis.
• Monitor for signs of heart failure; use cautiously in patients with unstable cardiac conditions.
• Review pregnancy and lactation status; the safety profile is not fully established.
• Consider age‑related dose adjustments for elderly patients.
• Ensure regular monitoring of blood glucose and HbA1c levels.

Gluformin Combi can interact with several medication groups, affecting its efficacy or safety.

Avoid

• Iodinated contrast agents used in imaging studies (risk of renal dysfunction).
• Strong CYP3A4 inhibitors that may increase sitagliptin concentrations.
• Cimetidine, which can raise metformin plasma levels.

Use with caution

• Other antidiabetic agents that increase hypoglycaemia risk (e.g., sulfonylureas, insulin).
• Diuretics that may affect renal clearance of metformin.
• ACE inhibitors or ARBs, especially in patients with compromised kidney function.
• Alcohol consumption, which can potentiate metformin‑related lactic acidosis.